Tissue Regenix’s (LON:TRX) replacement skin has continued to generate impressive results in a Manchester-based trial to treat chronic leg ulcers.
All twenty trial patients treated with Tissue Regenix’s dCELL Dermis saw a significant reduction in their wounds while nine were completely healed.
Tissue Regenix's dCELL Dermis is human skin that has been treated with its dCELLprocess, a patented technology that involves taking human or animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the risk of rejection.
The ongoing trial is being carried out in conjunction with the NHS Blood and Transplant division and is focused on people who have suffered with chronic ulcers for more than four years.
Tissue said as well as nine patients being healed, the surface area of all of the patient’s ulcers had halved in size, with volume also reduced significantly. The results were after six weeks.
The study also showed that the new skin could applied in 30- 40 minutes without hospital admission - in out-patient clinics and potentially GP surgeries - and can be tailored to fit a wound.
Dr Ardeshir Bayat, the trial's principal investigator at the University Hospital of South Manchester said: "These are encouraging interim results. The decellularised matrix appears to be providing a 'kick start' to heal these difficult wounds.
"Chronic wounds of the lower leg are a clinical challenge and their on-going treatment costs the NHS in excess of £400m per annum. Therefore a novel solution that can both reduce these costs and simultaneously offer a more effective treatment strategy has been long overdue."
Antony Odell, Tissue Regenix’s managing director added: "People who suffer with chronic leg ulcers often do so for many years. Traditional treatments using compression bandages are not effective in many cases and require regular hospital visits and the associated disruption to their daily lives.
"However, early results from this trial indicate that our dCELLtechnology could play an important role in treating patients who endure this painful condition, as well as deliver cost effective solution to the NHS by negating the need for regular treatment over a prolonged period."
Odell added that the company expects to publish the results of a pre-clinical knee cartilage replacement trial before the end of the year, while a number of different products including the ligament and cardiac patch are due to enter preclinical studies.
Tissue Regenix had also been selected as one of only twenty UK healthcare companies to attend the Future Healthcare Mission to showcase the best in UK medical and healthcare science and technology to US investors and business partners, he said.
“We believe Tissue Regenix is an excellent example of a British company with world-beating technology, which is based on research conducted in UK universities and pioneered through patient treatment in the NHS."
Tissue had net cash at the end of July of £26.1 mln. The company raised £25m through a share placing in December.
Losses in the half year rose to £1.87 mln from £1.34 mln reflecting the heavy product development currently underway, it said.